ESMO ADVANCED COURSE PROGRAMME
BIOMARKERS FOR PRECISION IMMUNO-ONCOLOGY
ACROSS TUMOURS

Zurich, Switzerland
17-18 November 2023

CO-CHAIRS
Samra Turajlic, United Kingdom
Benedikt Westphalen, Germany

SPEAKERS
Roberto Figueroa Salgado, Belgium
Marie-Dominique Galibert, France
Michael Hubank, United Kingdom
Lena Illert, Germany
Kevin Litchfield, United Kingdom
Christophe Massard, France
Miriam Molina, United Kingdom
Chantal Pauli, Switzerland
Etienne Rouleau, France

LEARNING OBJECTIVES

- To understand the concept of biomarker driven treatment
- To gain insights into the technical and clinical aspects of biomarker testing
- To understand the clinical implications of molecularly guided therapy options
- To integrate this knowledge into clinical decision making

Friday, 17 November

09:00-09:10 Welcome and introduction
10’ Welcome and Learning Objectives Introduction
Samra Turajlic, UK and Benedikt Westphalen, DE

09:10-10:45 Session 1 – Molecular target / Family of targets – DNA damage and mutational signatures

15’ Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
TBD
5’ Q&A

15’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Etienne Rouleau, FR
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Chantal Pauli, CH
10’ Q&A

15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Benedikt Westphalen, DE
10’ Q&A
10:45–11:15  Coffee break

11:15–12:50  Session 2 – Molecular target / Family of targets – FGFR

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
    Lena Illert, DE
7’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
    Christophe Massard, FR
7’  Q&A

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
    Marie-Dominique Galibert, FR
10’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board
    Lena Illert, DE
10’  Q&A

12:50–13:50  Lunch

13:50–15:25  Session 3 – Molecular target / Family of targets – RAS

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
    Miriam Molina, UK
7’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
    Benedikt Westphalen, DE
7’  Q&A

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
    Michael Hubank, UK
10’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board
    Miriam Molina, UK
10’  Q&A

19:30  Networking Dinner
### Saturday, 18 November 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 4 – Molecular target / Family of targets – Immune infiltration and immune checkpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-12:00</td>
<td></td>
</tr>
</tbody>
</table>
| 25’    | Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
|        | Kevin Litchfield, UK                                                                       |
| 10’    | Q&A                                                                                       |
| 25’    | Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
|        | Samra Turajlic, UK                                                                        |
| 10’    | Q&A                                                                                       |
| 20’    | Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
|        | Roberto Figueroa Salgado, BE                                                              |
| 10’    | Q&A                                                                                       |
| 10:40-11:10 | Coffee break                                                                             |
| 15’    | A clinicopathological case presented and discussed by a Molecular Tumour Board            
|        | Lena Illert, DE                                                                           |
| 10’    | Q&A                                                                                       |
| 15’    | Value/health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)    
|        | Michael Hubank, UK                                                                        |
| 10’    | Q&A                                                                                       |
| 12:00-12:15 | Synthesis and wrap-up                                                                    |
|        | Samra Turajlic, UK and Benedikt Westphalen, DE                                           |
| 12:15-13:15 | Lunch                                                                                  |